Depression treatment may alter Alzheimer's biomarkers, study suggests

NCT ID NCT05004987

Recruiting now Knowledge-focused Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether treating depression with a common antidepressant (escitalopram) can change brain and blood markers linked to Alzheimer's disease. Researchers will compare the drug to a placebo in 60 adults aged 60 and older who have major depression but no memory problems. The goal is to understand how depression treatment might affect Alzheimer's risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE MAJOR DEPRESSIVE DISORDER

Contacts and locations

Locations

NYU Langone Health
RECRUITING

New York, New York, 10016, United States
Nathan S. Kline Institute for Psychiatric Research
RECRUITING

Orangeburg, New York, 10962, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.